SCHEMBL1384932

SCHEMBL1384932

CSc1nccc(-c2cc3cn[nH]c3nc2-c2ccccc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
AKT1 P31749 11/20 0.43
AKT2 P31751 11/20 0.43
MAPK14 Q16539 2/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
CSNK1E P49674 1/20 0.43
LMNA P02545 1/20 0.41
NTRK1 P04629 1/20 0.40
CCNT1 O60563 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CDK9 P50750 1/20 0.40
CCNA1 P78396 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386407 0.88 MAPK14 (0.52) ADORA2AADORA2BADORA1MAPK14MAPK13
SCHEMBL1384875 0.85 MAPK14 (0.45) ADORA2AADORA2BADORA1MAPK14MAPK13
SCHEMBL4054613 0.83 ADORA2B (0.67) ADORA2AADORA2BADORA1LMNACCNT1
SCHEMBL1383884 0.81 MAPK14 (0.46) AKT1AKT2MAPK14MAPK13MAPK12
SCHEMBL6132086 0.80 TGFBR1 (0.50) AKT1MAPK14MAPK13MAPK12MAPK11
SCHEMBL29894085 0.78 ADORA2A (0.67) ADORA2AADORA2BADORA1AKT1MAPK14
SCHEMBL2933510 0.77 RPS6KB1 (0.52) AKT2MAPK14MAPK13MAPK12MAPK11
SCHEMBL2926500 0.77 DYRK1A (0.47) ADORA2AADORA2BADORA1AKT1AKT2
SCHEMBL2933513 0.77 RPS6KB1 (0.52) AKT2MAPK14MAPK13MAPK12MAPK11
SCHEMBL6070097 0.76 TGFBR1 (0.60) AKT1AKT2MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 ADORA2A 3463/4885ADORA2B 4238/4885ADORA1 4004/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA2A 3970/4885ADORA2B 4436/4885ADORA1 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.